Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?

To: D.B. Cooper who wrote (12850)	4/8/2004 8:58:04 AM
From: Pedro Joaristi	Read Replies (1) \| Respond to of 13815

Buying this stock is like going to the , but if the below is validated by an independent source, we will have here the next Genentech: Press Release Source: BioCurex, Inc. BioCurex Test Detects 90% of Leading Cancer Killer Monday April 5, 8:30 am ET RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--April 5, 2004--BioCurex Inc. (OTCBB:BOCX - News) announces results for lung cancer detection using its proprietary Serum-RECAF(TM) test. The results confirm 90% sensitivity with 95% specificity*. The findings further substantiate the use of RECAF(TM) as a universal cancer marker with a potential market size of $2 billion per year for all cancers. The study included 32 lung cancer patients and 103 normal donors with statistical verification. Dr. Moro commented: "Lung cancer is a terrible disease. It kills more people than any other type of cancer and it kills in a terrible way, by asphyxiation. It is gut wrenching to realize that even thought this is a preventable disease, the number of new cases and s keeps increasing each year. It is well established that early diagnosis results in better prognosis and that is why it was so important to develop a sensitive lung cancer test that catches 90% of cases with only 5% of false positives. Moreover, there is no other test that can detect lung cancer at the present time. The ultimate benefit to society could be enormous." These results are consistent with those obtained for other types of cancer and strengthen the concept of using Serum-RECAF(TM) as a valid test for screening the general populations for cancer. Since lung cancer, as well as many other cancers, is difficult to detect, the overall value of the RECAF technology in human and market terms is significant. Dr. Moro further stated, "It is not well understood by the general public, that we have very few ods available to tell if a person has a cancer. In fact, for most cancers, there are no existing specific tests. This is why RECAF is such a valuable technology. Even if we could only detect one type of cancer, we would have a significant discovery, but the studies strate that we obtain continued excellent results in many differing types of cancers and at very high detection values. We are very excited about our potential as a biotech company." About lung cancer: Lung cancer is now the most common form of cancer diagnosed in the United States and a major cause of . Lung cancer accounts for 14% of all cancers and 28% of all cancer s. At present, more Americans die from lung cancer than from breast, prostate, and colorectal cancers combined. Lung cancer has surpassed breast cancer as the most common type of cancer in women. Smoking costs the United States approximately $97.2 billion each year in health-care costs and lost productivity. It is directly responsible for 87 percent of lung cancer cases and causes most cases of emphysema and chronic bronchitis. About BioCurex: BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (OTCBB:BOCX - News), visit our website at www.biocurex.com. Don, your MAGS looking good... Pedro